ANI Pharmaceuticals (ANIP)

[Just the facts maam]

Something to consider.

We know that in order to maximize value to ANIP investors, Przybyl was looking for a co-promotion deal.

2016 ANIP appears to have struck a deal for libigel as indicated by the three new patent applications, letting the Libigel trademark expire without applying for a replacement name and letting.

September 2016 they met with Roth Capital in New York and Boston.

June 12, 2017 - ANIP filed an S-3 Form for $350 million shelf registration.

If the shelf registration was suppose to be used to get a sales team up and running, the lower the PPS the more shares they will have to issue to fund ramping up the sales force.

A formal sales process could be a way to get share price elevated without actually selling the company. If bids come in but lower then what they deem acceptable the BOD can't recommend it to shareholders however the highest bid may be divulged. This could generate significant PPS gains. Now bidders are bound by confidentiality agreements. Therefore potentially ANIP is able to either get fair value in a sale or raise PPS significantly to minimize issuance of shares to fund setting up a sales team, without breaking their non-disclosure agreement.

Obviously this is just a possible theory. If it actually is what's happening, it is brilliant.

JMHO